Turkey offers sarcoma treatment across 10-20 medical centers, including Anadolu Medical Center, Memorial Şişli Hospital, and Hisar Intercontinental. These centers collectively treat over 1,200 international patients annually for sarcoma, with Anadolu Medical Center serving approximately 200+ foreign patients. Leading hospitals employ robotic surgery, proton therapy, and targeted immunotherapy.
Anadolu holds JCI, OECI, and ESMO accreditations, while Memorial Şişli maintains JCI certification. Five-year survival rates reach 40-50% overall, with 70-80% for stage I patients versus 20-30% for advanced cases using innovative protocols: isolated limb perfusion and targeted VEGFR/PDGFR inhibitor therapy.